Evaluating diagnostic methods for Dementia with Lewy Bodies
Official title: Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach: EEG, Cognitive, Biological and MRI Biomarkers
Run by Assistance Publique - Hôpitaux de Paris · NCT06068361 · Data updated 2026-11-12
This study is testing a new way to diagnose Dementia with Lewy Bodies by using different brain scans and blood tests to see if they can improve accuracy for patients with this condition.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 55 Years to 85 Years |
| Sex | All |
| Enrollment | 130 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, France) |
| Status | Recruiting |
| Started | September 11, 2024 |
| Main results expected | September 2027 |
| Study ends | September 2027 |
| Registry record updated | March 27, 2025 |
| Trial ID | NCT06068361 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with probable DLB or Alzheimer's disease, as well as control subjects with subjective cognitive impairment.
✕Probably not a fit
Patients with contraindications to MRI or those with other neurological or psychiatric disorders that could affect cognitive assessment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to improve the diagnosis of Dementia with Lewy Bodies (DLB) by utilizing a multimodal approach that combines EEG, MRI, and plasma biomarkers. Over a period of 24 months, the study will include 50 probable DLB patients, 50 Alzheimer's disease patients, and 30 control subjects. The research will employ machine learning techniques to analyze the data collected from various diagnostic modalities, with the goal of identifying the most effective combination for accurate diagnosis. The study is conducted at the Cognitive Neurology Center in Paris.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and timely diagnoses of Dementia with Lewy Bodies, improving patient management and treatment outcomes.
How similar studies have gone: Other studies have shown promise in using multimodal approaches and machine learning for improving diagnostic accuracy in neurodegenerative diseases, suggesting potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria for DLB ant AD patients: * Neuropsychological assessment possible (good level in French language, absence of visual/auditory deficit limiting the cognitive assessment) * Dementia with Lewy bodies according to the revised criteria of Mc Keith 2017 or probable AD defined according to McKhann 2011 criteria including CSF biomarkers (an abnormal level of beta-amyloid 1-42 protein \[Ab42\] or a pathological Ab42/Ab40 ratio and an abnormal level of phosphorylated tau \[p-tau\]) Inclusion Criteria for control patients: * Neuropsychological assessment possible (good level in French language, absence of visual/auditory deficit limiting the cognitive assessment) * MMSE (Mini-mental State Examination) greater than or equal to 28, normal MemScreen test results, normal brain MRI and normal neurological examination Exclusion Criteria (for all) : * Contraindication to MRI * Other neurological or psychiatric or toxic/iatrogenic disorders that may account for the cognitive impairment or for EEG abnormalities * Any unstable medical pathology and/or that may account for the cognitive impairment
Where it's running
-
Centre de neurologie Cognitive
Paris, France, France Recruiting
Study contacts
- Study coordinator: Claire PAQUET, MDPhD
- Email: claire.paquet@aphp.fr
- Phone: 0140054313
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood tests using plasma biomarkers to diagnose and track Alzheimer’s disease
A large, year-long study in Milan is testing whether blood markers can help diagnose Alzheimer’s and predict how it will progress in people with memory concerns.
-
Lifestyle for Brain Health — Time-Restricted Eating and Mindfulness
This 9-month program tests whether combining yoga-based mindfulness with time-restricted eating improves cognition, physical fitness, metabolism, and plasma tau levels in adults 60–80 with subjective or mild cognitive impairment and positive pTau217.
-
Nutrition and exercise program for brain health in older adults
This study tests whether a 9-month program of exercise and nutrition can help improve brain health and physical function in older adults at risk for Alzheimer's disease.
-
Hearing care to reduce neuropsychiatric symptoms in people with Alzheimer's and related dementias
This trial will try a tailored, community-delivered hearing care program using HEARS devices to see if it improves communication, reduces neuropsychiatric symptoms, and eases caregiver distress in English-speaking older adults with Alzheimer's disease or related dementias who have untreated hearing loss.
-
Collecting data on neurodegenerative diseases progression markers
This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.
-
Evaluating acupuncture for Alzheimer's treatment in different genetic groups
This study is testing if acupuncture can help people with mild-to-moderate Alzheimer's disease feel better, especially looking at how it works for those with and without a specific gene.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.